Cosciens Biopharma (CSCI) Q1 2026 earnings summary

Executive summary

• Achieved consolidated net income of $10.8 million for Q1 2026, reversing a net loss of $3.7 million in Q1 2025, mainly due to $10.9 million income from discontinued operations after deconsolidating German subsidiaries.

• Revenue increased to $1.9 million from $1.4 million year-over-year, driven by higher sales volumes.

• Operating expenses reduced to $1.5 million from $3.0 million, reflecting cost-cutting in SG&A and R&D.

Financial highlights

• Cash and cash equivalents stood at $5.0 million as of March 31, 2026.

• Net loss from continuing operations narrowed to $0.2 million from $2.7 million year-over-year.

• Gross margin improved by $0.4 million compared to Q1 2025.

Outlook and guidance

• Plans to suspend SEC reporting obligations via share reorganization, pending shareholder and regulatory approval at the June 17, 2026 meeting.

• Focus shifting to growth opportunities after cost structure improvements and program rationalization.